Generated October 30, 2026 at 8:30 PM ET
· Covers October 30 trading day
· 10 of 225 ready 8-Ks selected
· AI-assisted overview
Ten 8-K filings were selected for Oct. 30, 2026, with leadership changes and transaction news among the most detailed. Visium Technologies disclosed its CEO's resignation after a disputed officer's certificate stating that previously issued financials should not be relied upon, while BioXcel Therapeutics closed a $57.5M asset sale to Teva and terminated four officers as it renames to BX Liquidation. Pelthos Therapeutics announced a stock merger with Castle Creek carrying up to $300M in D-Fi milestones plus a $57.5M PIPE, Pluri agreed to take a 50% stake in ZEO ScientifiX under an exclusive regenerative-medicine license, and LyondellBasell said it will sell its Houston Refining site to a Valero subsidiary for $320.5M. Acumen Pharmaceuticals reported that its Phase 2 ALTITUDE-AD trial missed the primary endpoint and that it plans to cease sabirnetug development. Three listing-standard items appeared — Nasdaq's delisting determination for Banzai International's Parabolic unit and NYSE non-compliance notices for Annovis Bio and Accendra Health, the latter two largely repetitive in substance — alongside quarterly results from Bank of the James and LyondellBasell.
VISM
VISIUM TECHNOLOGIES, INC.
leadership
negative
materiality 0.85
October 30, 2026, 5:24 PM ET
Visium CEO Taylor resigns after claiming FY2016-2026 financials unreliable; CFO Lucky named interim CEO
- Paul R. Taylor resigned Oct 26, 2026 as Chairman, CEO and director, citing disagreement over the Company's evaluation of previously issued financial statements.
- Taylor's officer's certificate to auditor Fruci & Associates II said audited FY2016-2026 and interim Dec 2015-Mar 2026 statements should no longer be relied upon.
- CFO Mark B. Lucky did not concur; the Board never authorized the certificate and has not concluded any statements need restating; a Special Committee is planned.
BTAI
BioXcel Therapeutics, Inc.
M&A
negative
materiality 0.88
October 30, 2026, 5:15 PM ET
BioXcel closes $57.5M Teva asset sale; CEO, CFO and two other officers terminated; renaming to BX Liquidation
- Teva paid $57.5M upfront cash (against which its $5.75M deposit was credited) for IGALMI (dexmedetomidine)/BXCL501 neuroscience assets; BXCL701 and BXCL702 were retained.
- Additional consideration: up to $67.5M development milestone on FDA approval of the IGALMI at-home-use sNDA, plus up to $20M in sales milestones at $250M and $500M annual net sales.
- Board terminated CEO Vimal Mehta, CFO Richard Steinhart, CSO Frank Yocca and CLO Javier Rodriguez effective 5 p.m. Oct 31, 2026; Mehta stays a director at $5,000/month.
PTHS
Pelthos Therapeutics Inc.
M&A
positive
materiality 0.85
October 30, 2026, 9:17 AM ET
Pelthos to merge with Castle Creek in stock deal; up to $300M D-Fi milestones plus $57.5M PIPE
- Pelthos to issue 5.2M shares to Castle Creek stockholders, who are expected to own ~32.5% of Pelthos fully diluted pre-PIPE, excluding contingent shares.
- Milestones: $50M on D-Fi clinical milestone by 6/30/2029; $50M on first U.S. sale; $50M at $100M TTM sales; $75M at $250M; $75M at $500M.
- Up to 5.8M contingent shares if FDA approves D-Fi by 3/31/2036 (cut 5%/quarter after 3/31/2031); 80% of PRV proceeds; 10% escrow.
BNZI
Banzai International, Inc.
regulatory
negative
materiality 0.82
October 30, 2026, 4:07 PM ET
Nasdaq moves to delist Parabolic Technologies after sub-$1 bid; authorized shares raised to 850M
- Nasdaq issued a Staff Delisting Determination on Oct 27, 2026 after PARA closed below $1.00 for 30 straight sessions (Sept 15-Oct 26); no 180-day cure period was offered.
- Cure period was denied because of cumulative 1-for-2,000 reverse splits: 1-for-10 on July 8, 2025, 1-for-20 on May 8, 2026 and 1-for-10 on Oct 27, 2026.
- Company intends to appeal by the Nov 3, 2026 deadline with a $20,000 hearing fee; absent a timely request, trading suspends at the open on Nov 5, 2026 and a Form 25-NSE is filed.
M&A
positive
materiality 0.75
October 30, 2026, 8:30 AM ET
Pluri to take 50% stake in ZEO ScientifiX via exclusive regenerative-medicine license; raises $1M at $1.10/share
- Pluri grants ZEO an exclusive U.S. license to manufacture and commercialize its regenerative medicine portfolio (aesthetics/skin care excluded), expandable to Latin America.
- Consideration: 41% of ZEO shares plus 50 Series D preferred shares carrying 51% of ZEO votes; cross-share swaps lift Pluri to 50% of ZEO with 4 of 7 board seats.
- Five-year ZEO warrants for 5% at $4.00/share and 2.5% at $5.50/share, plus another 5% if ZEO's 10-day VWAP reaches $5.50; closing due within 90 days of Oct 26, 2026.
regulatory
negative
materiality 0.70
October 30, 2026, 5:10 PM ET
Annovis Bio gets NYSE non-compliance notice; 30-day average market cap $48.4M, equity deficit $(4.3)M
- NYSE notice dated Oct 29, 2026 cites Section 802.01B: 30 trading-day average market cap below $50M ($48.4M as of Oct 28) with stockholders' equity under $50M.
- Last reported stockholders' deficit was approximately $(4.3) million as of June 30, 2026, per the notice.
- Company will submit a cure plan within 45 days; NYSE has 45 days to accept, with a 9-month cure period from notice receipt.
ACH
ACCENDRA HEALTH INC/VA/
regulatory
negative
materiality 0.70
October 30, 2026, 4:50 PM ET
Accendra Health gets NYSE notice over $50M market cap and equity listing standard
- NYSE notified Accendra on Oct. 27, 2026 that it falls below Section 802.01B: average market cap under $50.0M over 30 trading days and stockholders' equity under $50.0M.
- No immediate delisting; ACH common stock continues trading on NYSE while the company pursues a cure.
- Company must submit a business plan within 45 calendar days showing how it will regain compliance within 18 months; NYSE would monitor quarterly if accepted.
ABOS
Acumen Pharmaceuticals, Inc.
other material
negative
materiality 0.95
October 30, 2026, 7:06 AM ET
Acumen's Phase 2 ALTITUDE-AD fails primary endpoint; sabirnetug development halted, cash conservation planned
- Phase 2 ALTITUDE-AD missed the primary iADRS endpoint at 18 months vs placebo at both the 35 mg/kg and 50 mg/kg doses; CDR-SB and other key secondary endpoints were not significant.
- Sabirnetug was generally well tolerated; ARIA-E occurred in ~10% of treated participants; PET SUVr showed statistically significant amyloid plaque reduction at weeks 36 and 76.
- Acumen plans to cease development of sabirnetug, including the open-label extension portion of ALTITUDE-AD, and to implement cash conservation measures.
BOTJ
BANK OF THE JAMES FINANCIAL GROUP INC
earnings
positive
materiality 0.72
October 30, 2026, 12:15 PM ET
Bank of the James Q3 EPS $0.73 vs $0.61; nine-month net income $9.34M; dividend raised 50% to $0.15
- Q3 2026 net income $3.32M, up $570K from $2.75M a year earlier; EPS $0.73 vs $0.61. Nine-month net income $9.34M ($2.05/share) vs $6.30M ($1.39).
- Quarterly cash dividend raised 50% to $0.15 per share from $0.10, payable December 4, 2026 to stockholders of record November 20, 2026.
- Net interest margin (tax-equivalent) 3.81% vs 3.44% in Q3 2025; net interest income after provision up ~18% to $9.69M. Interest expense fell 8.90% to $3.16M.
LYB
LyondellBasell Industries N.V.
earnings
positive
materiality 0.72
October 30, 2026, 6:31 AM ET
LyondellBasell Q3 net income $758M, EPS $2.32; selling Houston Refining site to Valero unit for $320.5M
- Sales $8.50B vs $7.73B a year earlier; net income $758M ($2.32 per diluted share) versus a $890M loss in Q3 2025.
- EBITDA $1.42B, or $1.51B excluding identified items, versus negative $480M EBITDA a year ago; nine-month diluted EPS $4.42 vs -$1.89.
- Agreed Oct. 29 to sell Houston Refining, L.P. and the former Houston refinery site to a Valero subsidiary for $320.5M; closing expected Q4 2026, subject to regulatory approval.